← Drugs Made In America Acquisition Corp. (DMAAU) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Drugs Made In America Acquisition Corp. (DMAAU)
Biotechnology · market cap $267M · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Drugs Made In America Acquisition Corp. (DMAAU) is a biotechnology-sector entity with a reported market cap of approximately $309M. Its sole disclosed asset is FS-1, a Phase 3 candidate targeting multidrug-resistant tuberculosis (MDR-TB). Financial details including cash, runway, share count, and price are not publicly disclosed in the available facts.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| FS-1 | Phase 3 | Tuberculosis, MDR |
Price & technical context
3-month
+2.4%
6-month
+5.4%
12-month
+5.4%
52-wk range
$10.40–$11.70
vs 50-day MA
+1.8%
vs 200-day MA
+3.7%
Realized vol
13.0%
Max drawdown
-9.3%
Daily closes through 2026-11-04. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for DMAAU (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.